Skip to main
HQY

HealthEquity (HQY) Stock Forecast & Price Target

HealthEquity (HQY) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 50%
Hold 7%
Sell 0%
Strong Sell 7%

Bulls say

HealthEquity reported a 13% year-over-year increase in custodial revenue, contributing to an adjusted EBITDA margin of 44.0%, which improved by 466 basis points compared to the previous year. The company experienced a significant increase in cash flow from operations, rising 28.4% to $339.2 million for the fiscal year 2026, showcasing strong operational efficiency. Additionally, total revenue for Q3 2026 rose 7.2% to $322.2 million, bolstered by an increase in total HSA assets, which reached $36.5 billion, reflecting a 13.6% year-over-year growth and enhanced member engagement.

Bears say

HealthEquity's projected FY/27 revenue and adjusted EBITDA estimates have been slightly downgraded, indicating potential challenges in maintaining growth momentum, with expected revenue now at $1.410 billion and adjusted EBITDA at $623.3 million. The stock is currently trading at multiples that suggest overvaluation compared to its high-growth SaaS peers, presenting a concerning discrepancy as its shares have declined 13% year-to-date. The company faces a multitude of risks, including intense competition, evolving regulations in the healthcare sector, reliance on third-party suppliers, and potential operational challenges, which contribute to a negative outlook on its stock.

HealthEquity (HQY) has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 50% recommend Buy, 7% suggest Holding, 0% advise Selling, and 7% predict a Strong Sell.

This aggregate rating is based on analysts' research of HealthEquity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HealthEquity (HQY) Forecast

Analysts have given HealthEquity (HQY) a Buy based on their latest research and market trends.

According to 14 analysts, HealthEquity (HQY) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $115.21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $115.21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HealthEquity (HQY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.